Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of DNL343 in healthy volunteers
NCT04268784Phase 1Completed
- Sponsor
- Denali Therapeutics Inc.
- Start
- Feb 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing DNL343 with Placebo (2 arms). Primary endpoints: Incidence and severity of treatment-emergent adverse events at 20 days, Area under the concentration-time curve from time zero extrapolated to infinity at 20 days and 5 more. Started Feb 2020; status: completed.
02
Drugs
DNL343
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04268784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04268784.